Readout 360: Prostate Cancer – Real World Implications of the CARD Study

home / read-out-360 / readout-360-prostate-cancer-real-world-implications-of-the-card-study

A key opinion leader discusses the CARD Study and how the emerging data has impacted the treatment of prostate cancer.

Recent Content

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

Contact Info

2 Commerce Drive
Cranbury, NJ 08512